Aveanna Healthcare (AVAH) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AVAH Aveanna Healthcare

Watchlist

4.580
+0.060+1.33%

Close Dec 20 16:00 ET

4.580
0.0000.00%

Post 20:01 ET

884.97MMarket Cap-13.09P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Analysts Conflicted on These Healthcare Names: Aveanna Healthcare Holdings (AVAH) and BioNTech SE (BNTX)
TipRanksNov 26 08:50 ET · Ratings
Truist Financial Maintains Aveanna Healthcare(AVAH.US) With Hold Rating, Announces Target Price $6
Moomoo NewsNov 15 07:31 ET · Ratings
Truist Financial Reaffirms Their Hold Rating on Aveanna Healthcare Holdings (AVAH)
TipRanksNov 15 07:06 ET · Ratings
NASDAQ New 52-Week Highs And Lows
Dow JonesNov 12 11:21 ET
UBS Maintains Aveanna Healthcare(AVAH.US) With Sell Rating, Raises Target Price to $3.2
Moomoo NewsNov 9 02:31 ET · Ratings
Aveanna Healthcare Holdings Inc. (AVAH) Q3 2024 Earnings Call Transcript Summary
moomoo AINov 8 21:44 ET · Conference Call

Comments

Iwill TradeScared

Oct 15 18:59

$Aveanna Healthcare (AVAH.US)$ testing

Iwill TradeScared

Oct 9 19:46

$Aveanna Healthcare (AVAH.US)$

Tonyco

Oct 6 12:11

Columns Cause and Effect

Oh, no, numbers did a thing!!!! PAN8C SELL
Anticipating rate cuts in September, businesses increased payrolls by re-hiring all the people they laid off earlier in the year or later to "protect margins."
Why wouldn't you try to get a head start on boosted demand for products?
Predictably, Old Money doesn't think past the week, so if nothing else, next week, will present entry points.
$ChromaDex (CDXC.US)$ Bioscience, aging products.
FY24 Estimates:
Sales growth +13% yoy
Gross marg...

September new jobs higher than expected, is this a 'soft landing' ?

Tonyco

Oct 5 22:23

$Aveanna Healthcare (AVAH.US)$
Estimates for FY24:
Sales growth : +5% YoY
EBITDA: +16% YoY
Net Income : +106% YoY
EPS + 104% YoY

Moomoo AI

Dec 13, 2023 04:40

Despite Aveanna Healthcare's recent rally, its P/S ratio remains low amid predictions its growth will lag industry standards. This suggests investor expectation of limited future growth and a reluctance to pay more for its current state, likely averting a substantial price rise soon.